NCT05215561 - Special Drug Use-results Survey to Evaluate Safety and Efficacy of Cosentyx in Pediatric Patients With PsV, PsA, or GPP | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 14, 2022

Primary Completion Date

September 28, 2024

Study Completion Date

September 28, 2024

Conditions

Psoriasis VulgarisPsoriatic ArthritisPustular Psoriasis

Interventions

OTHER

Cosentyx

There was no treatment allocation. Patients administered Cosentyx by prescription that had started before inclusion of the patient into the study were enrolled.

Trial Locations (21)

467-8602

Novartis Investigative Site, Nagoya

814 0180

Novartis Investigative Site, Fukuoka

807-8556

Novartis Investigative Site, Kitakyushu

080 0013

Novartis Investigative Site, Obihiro

064-0807

Novartis Investigative Site, Sapporo

310-0015

Novartis Investigative Site, Mito

920-0293

Novartis Investigative Site, Kahoku-gun

602-8026

Novartis Investigative Site, Kamigyō-ku

602-8566

Novartis Investigative Site, Kyoto

983 8512

Novartis Investigative Site, Sendai

630-0293

Novartis Investigative Site, Ikoma

570-8507

Novartis Investigative Site, Moriguchi

589 8511

Novartis Investigative Site, Ōsaka-sayama

591 8025

Novartis Investigative Site, Sakai

569-8686

Novartis Investigative Site, Takatsuki

104 8560

Novartis Investigative Site, Chuo Ku

160-0023

Novartis Investigative Site, Shinjuku Ku

130-8587

Novartis Investigative Site, Sumida-Ku

010-8543

Novartis Investigative Site, Akita

616-8313

Novartis Investigative Site, Kyoto

641-0051

Novartis Investigative Site, Wakayama